State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau 999078, People's Republic of China.
State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau 999078, People's Republic of China; School of Pharmacy, Youjiang Medical University for Nationalities, Baise 533000, People's Republic of China.
Bioorg Chem. 2021 Apr;109:104740. doi: 10.1016/j.bioorg.2021.104740. Epub 2021 Feb 18.
Six new non-classical cardenolides (1-6), and seventeen known ones (7-23) were isolated from Calotropis gigantea. All cardenolides showed inhibitory effect on hypoxia inducible factor-1 (HIF-1) transcriptional activity with IC of 8.85 nM-16.69 µM except 5 and 7. The novel 19-dihydrocalotoxin (1) exhibited a comparable HIF-1 inhibitory activity (IC of 139.57 nM) to digoxin (IC of 145.77 nM), a well-studied HIF-1 inhibitor, and 11, 12, 14, 16 and 19 presented 1.4-15.4 folds stronger HIF-1 inhibition than digoxin. 1 and 11 showed a dose-dependent inhibition on HIF-1α protein, which led to their HIF-1 suppressing effects. Compared with LO2 and H9c2 normal cell lines, both 1 and 11 showed selective cytotoxicity against various cancer cell lines including HCT116, HeLa, HepG2, A549, MCF-7, A2780 and MDA-MB-231. Moreover, a comprehensive structure-activity relationship was concluded for these non-classical cardenolides as HIF-1 inhibitors, which may shed some light on the rational design and development of cardenolide-based anticancer drugs.
从大猪笼草中分离得到了 6 种新的非经典强心苷(1-6)和 17 种已知的强心苷(7-23)。除了 5 和 7 之外,所有的强心苷都显示出对缺氧诱导因子-1(HIF-1)转录活性的抑制作用,IC 为 8.85 nM-16.69 µM。新型 19-去氢猪毛菜苷(1)对 HIF-1 的抑制活性(IC 为 139.57 nM)与地高辛(IC 为 145.77 nM)相当,地高辛是一种研究得很好的 HIF-1 抑制剂,11、12、14、16 和 19 的 HIF-1 抑制作用比地高辛强 1.4-15.4 倍。1 和 11 对 HIF-1α 蛋白呈剂量依赖性抑制,导致其 HIF-1 抑制作用。与 LO2 和 H9c2 正常细胞系相比,1 和 11 对包括 HCT116、HeLa、HepG2、A549、MCF-7、A2780 和 MDA-MB-231 在内的多种癌细胞系均表现出选择性细胞毒性。此外,对这些非经典强心苷作为 HIF-1 抑制剂的综合构效关系进行了总结,这可能为基于强心苷的抗癌药物的合理设计和开发提供一些启示。